• Alamzeb Manan


ABSTRACTThis is an 8-week open study in which the effect and tolerance of Famotidine, in a dose of 40mg nocte was tried for the treatment of duodenal ulcer in 22 patients. Assessment was madeclinically, biochemically and endoscopically. The healing rate at the end of 8 weeks was 95.45%.The drug was well tolerated with no significant side effect. In conclusion, Famotidine is an effectiveand safe Duodenal ulcer healing drug, which is well tolerated and has minimal side effects


Bonnivie, O. Survival in peptic ulcer, Gastroenterology 1978; 75: 1055-60.

Gough K.R. Korman M.G. Bradham K.D. et al. Ranitadine and Cimetidine in prevention of duodenal

ulcer. Lancet 1989, (No. 2): 659-62.

Smith, J.R., Gamal, M., Chremos., A.N. and Graham D.Y. Famotidine a new H2 receptor antagonist.

Effect on parietal, non-parietal and pepsin secretion in man Dig. dis. sci. 1985; 30: 308)'

Rayan. J.R., Cremus, A.N. and Vargas R. Inhibition of basal nocturnal and mean stimulated acid

secretion by Famotidine Gastroenterology 1985; 88: 1564.

Liang. T. Absence of androgenic receptor affinity for MK-208, a new H2 receptor antagonist Clin.

Res., 18: 105.

Rashid R and Khan M.A, Treatment of acute duodenal ulcer with Famotidine and its comparison

with other H2 receptor antagonists JPMA 1990; 136-7.